Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis [PDF]
Vojnosanitetski Pregled, 2020 Backgroun/Aim. Although majority of guidelines recommend triazoles (voriconazole, posaconazole, itraconazole and isavuconazole) as first-line therapeutic option for treatment of invasive aspergillosis, echinocandins (caspofungin, micafungin and ...
Uzelac Sanja M. +4 more
doaj +2 more sources
Review on Current Status of Echinocandins Use
Antibiotics, 2020 Fungal infections are rising all over the world every year. There are only five medical compound classes for treatment: triazoles, echinocandins, polyenes, flucytosine and allylamine.
Martyna Mroczyńska +1 more
doaj +2 more sources
The current place of echinocandins in the treatment and prophylaxis of invasive fungal infections [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2020 Invasive fungal infections continue to show steady growth among various patient populations, accompanied by high rates of both morbidity and attributive mortality.
Veselov A.V.
doaj +2 more sources
Echinocandins have an alternative mode of action on biomimetic membranes that is not directly related to the functioning of (1,3) beta-glucan synthase. [PDF]
Cell Death DiscovEchinocandins are the preferred agents for treating invasive candidiasis; however, rising resistance in Candida species poses a significant challenge for patient care.
Malykhina AI +5 more
europepmc +2 more sources
Insight into advances for the biosynthetic progress of fermented echinocandins of antifungals
Microbial BiotechnologyInvasive fungal infections have increased remarkably, which have become unprecedented concern to human health. However, the effectiveness of current antifungal drugs is limited due to drug resistance and toxic side‐effects.
Kaili Jiang +3 more
doaj +2 more sources
Journal of Fungi, 2023 This study aimed to evaluate the effectiveness of fluconazole and echinocandins in the treatment of candidemia caused by both fluconazole- and echinocandin-susceptible common Candida species. A retrospective study which enrolled adult candidemia patients
Jong Hun Kim, Jin Woong Suh, Min Ja Kim
doaj +2 more sources
Global surveillance of <i>Candida albicans</i>: MIC distributions, resistance patterns, and temporal trends from the Antimicrobial Testing Leadership and Surveillance program (2015-2024). [PDF]
Antimicrob Agents ChemotherCandida albicans remains the predominant cause of invasive candidiasis worldwide, yet comprehensive global analyses of its antifungal susceptibility trends remain scarce. In this decade-long study, we evaluated 6,342 C.
Cai G, Zhang Z.
europepmc +2 more sources
Journal of Fungi, 2020 Candida haemulonii complex (C. haemulonii, C. duobushaemulonii and C. haemulonii var. vulnera) is well-known for its resistance profile to different available antifungal drugs.
Lívia S. Ramos +3 more
doaj +2 more sources
Antifungal effects of echinocandins diminish when exposed to intestinal lumen contents: a finding with potentially significant clinical implications [PDF]
Frontiers in PharmacologyEchinocandins, a prominent class of antifungals, are known for their broad-spectrum activity and favorable safety profiles. However, their bioavailability and efficacy via oral route are suboptimal. In this study, caspofungin and micafungin, the two most
Sepideh Mehravar +5 more
doaj +2 more sources
Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins [PDF]
Journal of Fungi, 2020 Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. It is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by
Guillermo Garcia-Effron
doaj +2 more sources